BioSpace44m
Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down
The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...
STAT22h
FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences
Peter Marks’ ouster comes at a time when the sector is already suffering through a years-long public markets slump.
US drug stocks fall as FDA vaccine chief ousted amid Trump health overhaul
The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year ...
Biotech Stocks Tumble on Reports FDA's Top Vaccine Regulator to Leave
As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited ...